医学
2型糖尿病
重症监护医学
糖尿病
人口
药品
药理学
环境卫生
内分泌学
作者
Harmanjit Singh,Jasbir Singh,Ravneet Kaur Bhangu,Mandeep Singla,Jagjit Singh,Farideh Javid
标识
DOI:10.1080/17512433.2023.2163386
摘要
It is an excellent option for use in older patients as studies in the geriatric population have shown encouraging results. Teneligliptin has a desirable pharmacokinetic profile that makes it a potential drug for use on an alternate-day basis. Teneligliptin has shown anti-diabetic efficacy even at a dose of 10 mg. These approaches may improve treatment satisfaction and patient compliance and can lower the cost; however, it is crucial to identify the subset of T2DM patients who can obtain maximum benefits. To verify these effects, large clinical investigations need to be planned and robust clinical evidence should be generated.
科研通智能强力驱动
Strongly Powered by AbleSci AI